Relmada Therapeutics Files 8-K with Key Agreements and Equity Sales

Ticker: RLMD · Form: 8-K · Filed: Mar 26, 2025 · CIK: 1553643

Relmada Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRelmada Therapeutics, Inc. (RLMD)
Form Type8-K
Filed DateMar 26, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, regulation-fd

TL;DR

Relmada filed an 8-K: material agreement, equity sales, and FD disclosure. Check for details.

AI Summary

On March 24, 2025, Relmada Therapeutics, Inc. filed an 8-K report detailing several key events. The filing indicates the entry into a material definitive agreement, unregistered sales of equity securities, and a Regulation FD disclosure. It also includes financial statements and exhibits, with the report being filed as of March 26, 2025.

Why It Matters

This 8-K filing signals significant corporate actions by Relmada Therapeutics, including potential new financing or strategic partnerships and the issuance of equity, which could impact its financial structure and stock.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities and material definitive agreements, which can introduce financial and operational risks.

Key Players & Entities

  • RELMADA THERAPEUTICS, INC. (company) — Registrant
  • March 24, 2025 (date) — Date of earliest event reported
  • March 26, 2025 (date) — Filing date
  • 2222 Ponce de Leon Blvd. , Floor 3 Coral Gables , FL 33134 (address) — Principal executive offices

FAQ

What is the nature of the material definitive agreement entered into by Relmada Therapeutics?

The filing does not specify the details of the material definitive agreement, only that one was entered into.

What type of equity securities were sold in the unregistered sale?

The filing mentions unregistered sales of equity securities but does not specify the type or amount.

What is the purpose of the Regulation FD Disclosure?

The filing indicates a Regulation FD Disclosure was made, but the specific content is not detailed in this summary.

When was Relmada Therapeutics, Inc. incorporated?

Relmada Therapeutics, Inc. was incorporated in Nevada.

What is the IRS Employer Identification Number for Relmada Therapeutics, Inc.?

The IRS Employer Identification Number for Relmada Therapeutics, Inc. is 45-5401931.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding RELMADA THERAPEUTICS, INC. (RLMD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.